AG真人官方

Madrigal Pharmaceuticals insiders and affiliated funds reported multiple purchases of Common Stock on 08/18/2025. The filings show aggregated acquisitions executed in multiple transactions at weighted-average prices ranging roughly from $353.76 to $372.50 per share. Following the reported purchases, the filings list two classes of beneficial ownership totals: approximately 193,000 shares and approximately 1,859,091鈥�1,848,963 shares across different line items, reflecting purchases by 667, L.P. and Baker Brothers Life Sciences, L.P., with Baker Bros. Advisors LP as adviser. Reporting persons include Baker Bros. entities, Julian C. Baker, Felix J. Baker and directors including Dr. Raymond Cheong. The filing is noted as the first of two Form 4s covering these changes.

Madrigal Pharmaceuticals, Inc. (MDGL) Rule 144 notice shows proposed and recent sales of common stock by an identified insider. The filing lists a proposed sale of 1,000 shares through Morgan Stanley Smith Barney with an aggregate market value of $390,224.20, slated for 08/20/2025 on NASDAQ. Those 1,000 shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filer also reported prior sales by the same person in the past three months: 2,000 shares on 08/18/2025 for $764,481.20 and 4,100 shares on 08/15/2025 for $1,503,481.48. The notice includes the standard insider representation that no undisclosed material adverse information is known.

Madrigal Pharmaceuticals General Counsel Kelley Shannon T reported multiple sales of common stock on 08/18/2025. The Form 4 shows a series of dispositions across eight reported transactions, including a 458-share sale to cover tax withholding related to RSU vesting and seven sales executed under a Rule 10b5-1 trading plan adopted November 7, 2024. Reported weighted-average prices for the 10b5-1 sales range roughly from $369.02 to $376.64 per share. Following these transactions the reporting person鈥檚 beneficial ownership declined from 10,019 shares to 9,173 shares.

Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 notice reports a proposed sale of securities by a person for whose account shares vested as restricted stock units. The filer plans to sell two lots of Common Stock through Morgan Stanley Smith Barney LLC on 08/18/2025: 458 shares (aggregate market value $169,386.72) and 846 shares (aggregate market value $312,884.64). Both lots were acquired on 08/15/2025 by vesting of restricted stock units from the issuer. The filing states there were no sales by the filer in the prior three months and includes the required attestation about material nonpublic information.

Madrigal Pharmaceuticals (MDGL) Form 144 filing shows a proposed sale of 2,000 common shares to be executed through Morgan Stanley Smith Barney on 08/18/2025 with an aggregate market value of $764,481.20. The filer states these 2,000 shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filing also discloses that the same person sold 4,100 shares on 08/15/2025 for gross proceeds of $1,503,481.48. The filer signs a representation that they are unaware of any undisclosed material adverse information about the issuer.

Kenneth Bate, a director of Madrigal Pharmaceuticals, filed a Form 4 reporting transactions on 08/15/2025. The filing shows an acquisition of 10,000 common shares at a price of $16.46, and contemporaneous sales totaling 10,000 shares in multiple transactions at weighted-average prices ranging from about $362.87 to $368.98. Following these trades, the reporting person鈥檚 direct beneficial ownership moved from 12,627 shares immediately after the acquisition to 2,627 shares after the sales. The Form also discloses a stock option with a $16.46 exercise price covering 10,000 underlying shares, which the filer states are fully vested and exercisable.

Madrigal Pharmaceuticals (MDGL) reported a Form 144 notice for the proposed sale of 4,100 shares of common stock through Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $1,503,481.48 based on the transaction and shows 22,289,014 shares outstanding for the issuer. The shares were acquired and are being sold on the same date by exercise of options under a registered plan and payment was made in cash. The filer reports nothing to report for securities sold during the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.

Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney on 08/15/2025 on NASDAQ with an aggregate market value of $3,652,008.00. The filer states the shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filing reports 22,289,014 shares outstanding, and shows no securities sold by the filer in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Janus Henderson Group plc reports beneficial ownership of 2,191,753 shares of Madrigal Pharmaceuticals common stock, representing 9.9% of the class. The filing breaks this down by reporting persons and subsidiaries: JHIUS may be deemed the beneficial owner of 2,173,828 shares (9.8%), and the reporting tables show shared voting and shared dispositive power over 2,191,753 shares with no sole voting or dispositive power.

The filer certifies these holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power of attorney authorizing named compliance officers to execute required ownership reports on the company鈥檚 behalf.